Avid Bioservices, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Nicholas Stewart Green MBA
- Full Time Employees
- 371
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2642 Michelle Drive Tustin CA United States of America 92780
- IPO Date
- Apr 4, 1994
- CIK
- 0000704562
- Website
- avidbio.com
- Similar Companies
- Business
- Avid Bioservices, Inc. operates as a dedicated contract development and manufacturing organization (CDMO) specializing in the biotechnology and biopharmaceutical industries. The company provides comprehensive biopharmaceutical drug substance services including process development; current good manufacturing practice (CGMP) clinical and commercial manufacturing of biologics; mammalian cell culture production; bulk packaging; purification; release and stability testing; regulatory submission support; upstream and downstream process development and optimization; analytical methods development; cell line development; product characterization; and quality and regulatory compliance services. Avid Bioservices also offers specialized manufacturing capabilities in cell and gene therapy (CGT) with a state-of-the-art CGMP facility designed to produce suspension culture batches up to 3,000 liters and adherent cultures utilizing fixed bed bioreactors, supported by advanced filling and capping technology under isolators, and extensive quality control laboratory space. Founded in 1981 and headquartered in Tustin, California, Avid Bioservices has progressively expanded its capacity and service offerings, commissioning a mammalian protein CGMP drug substance Line 3 facility in 2023 and completing construction of new CGMP manufacturing suites dedicated to cell and gene therapy by early 2024, positioning the company to generate up to approximately $400 million in annual revenue. The company has a track record of producing over 250 commercial batches and 5 commercial products marketed in more than 90 countries, maintaining a flawless quality record for over a decade. Recently, in late 2024, Avid Bioservices was acquired in an all-cash transaction valued at approximately $1.1 billion by GHO Capital Partners and Ampersand Capital Partners, marking a major strategic shift to accelerate growth. This acquisition provides Avid with access to expanded capital, expertise, and networks aimed at enhancing service capabilities, scaling operations, and expanding geographic reach. The new ownership supports Avid’s focus on lifecycle manufacturing solutions spanning from concept through commercial supply, emphasizing investments in bioprocess optimization, analytical testing, regulatory compliance, and state-of-the-art manufacturing technologies. Avid Bioservices primarily serves biotechnology and pharmaceutical companies globally, operating within the healthcare and biotechnology sectors with a strong commitment to supporting complex biologics and advancing cell and gene therapy manufacturing capabilities. The company's evolution from a subsidiary of Peregrine Pharmaceuticals to an independent leading CDMO reflects its long-standing industry presence and forward-looking growth strategy under new ownership. This comprehensive suite of biologics manufacturing and development services combined with recent facility expansions and the strategic acquisition positions Avid Bioservices as a key player in the global CDMO market focused on innovative biologics and next-generation therapies.
Company News
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S.
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility